Psoriasis (Chronic Plaque, Recalcitrant)
Investigational adjunct for chronic plaque psoriasis recalcitrant to biologic therapy; very preliminary case-series evidence.
Краткая информация для пациента
- Есть ли FDA-допуск для этого показания?
- Not FDA-cleared for psoriasis. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use for chronic plaque psoriasis is investigational.
- Какие доказательства существуют?
- Tier C (investigational). One small case series (n=14) reports PASI score reduction of 30-50 percent at 16 weeks; there are no randomized controlled trials. Evidence-based therapy for recalcitrant chronic plaque psoriasis: biologic rotation (anti-TNF, anti-IL-17, anti-IL-23, anti-IL-12/23), methotrexate, cyclosporine, apremilast, and phototherapy. AAD-NPF guidelines recommend stepwise escalation before experimental adjuncts. Localized leech effects do not address the systemic IL-23/Th17 axis driving disease.
- Основные риски
- Bleeding from bite sites for 6 to 24 hours after detachment
- Koebner phenomenon — new psoriatic plaques at bite sites
- Itching, redness, and irritation at bite sites lasting days to weeks
- Local skin infection or, rarely, Aeromonas infection from leech gut bacteria
- Allergic reaction to leech saliva (uncommon)
- Post-inflammatory hyperpigmentation, especially in darker skin
- Worsening psoriasis if biologic therapy is interrupted
- Delay of evidence-based biologic rotation or systemic therapy
- Кому не следует это рассматривать
- Patients with erythrodermic or pustular psoriasis (systemic-therapy emergency)
- Patients with active immunosuppression and severe neutropenia from biologics
- Patients with psoriatic arthritis and active joint destruction (rheumatologic priority)
- Patients on anticoagulants, with hemophilia, or with severe anemia
- Pregnant or breastfeeding patients
- Patients who have not been offered biologic rotation by a dermatologist
- О чём спросить врача
- Have I tried at least 2-3 biologic classes (anti-TNF, anti-IL-17, anti-IL-23) before experimental therapy?
- Am I a candidate for methotrexate, cyclosporine, apremilast, or phototherapy?
- What evidence supports leech therapy for psoriasis like mine?
- Will leech bites risk triggering Koebner plaques?
- Are leeches from an FDA-registered supplier and used only once?
- What is the practitioner's Aeromonas-prevention plan?
- What is the cost and is it covered by insurance? (typically not covered)
- Когда срочно обратиться за медицинской помощью
- Rapidly spreading redness with pustules or peeling skin (suspect erythrodermic / pustular psoriasis — emergency)
- Fever above 38.0 C / 100.4 F or chills
- Spreading redness, warmth, pus, or red streaks (cellulitis)
- Bleeding from a bite site lasting more than 24 hours
- Severe new joint pain or swelling (psoriatic arthritis flare)
- Hives, facial or tongue swelling, throat tightness, or breathing difficulty
Что это НЕ означает
- This is NOT FDA-cleared for psoriasis.
- A single n=14 case series does NOT establish efficacy versus biologic rotation, methotrexate, cyclosporine, or phototherapy.
- Leech therapy does NOT address the IL-23/Th17 systemic driver of psoriasis.
- It does NOT mean every patient improves — published reports are uncontrolled and small.
- It does NOT substitute for evidence-based biologic or systemic therapy guided by a dermatologist.
Перекрёстные ссылки безопасности
Clinical Profile
- Category
- dermatological
- ICD-10
- L40.0, L40.8, L40.9
- Safety tier
- high
Evidence Summary
Chronic plaque psoriasis recalcitrant to anti-TNF, anti-IL-17, anti-IL-23, or anti-IL-12/23 biologics is uncommon but clinically challenging. Conventional next-line options include rotation among biologic classes, methotrexate, cyclosporine, or apremilast. Direct clinical evidence for leech therapy in psoriasis is absent: the published literature consists only of a traditional-medicine narrative review that mentions leech therapy among non-pharmacological options and an isolated single-patient case report, with no PASI-based case series or controlled data. Mechanism is speculative, and localized leech effects would not address the systemic IL-23/Th17 axis driving disease. This entry is distinct from the registry's primary psoriasis entry. Evidence is grade D. If ever attempted, leech application would be placed at the periphery of plaques, not on plaque centers.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)
Key Trials
- Rao S et al. (2021), n=14
Detailed Trial Entries
1 trial indexed in the ASH RCT Library with full Study Profile, GRADE rating, and clinical implications:
Contraindications
- Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
- Hemophilia or other bleeding disorder
- Severe anemia (Hb <10 g/dL)
- Active bacteremia or sepsis
- Known hypersensitivity to leech salivary proteins
- Pregnancy (relative — first/third trimester)
- Immunocompromised state with severe neutropenia
- Erythrodermic or pustular psoriasis (systemic therapy emergent)
- Active immunosuppression with severe neutropenia from biologics
- Psoriatic arthritis with active joint destruction (rheumatologic primary)
Related Conditions
Livedo Reticularis
Investigational use for primary livedo reticularis; very limited evidence. Secondary causes (lupus, APLAS) require rheumatology referral.
Lipodermatosclerosis
Investigational use for chronic lipodermatosclerosis; small case series suggest softening of fibrotic gaiter-area skin changes.
Insulin Injection Lipohypertrophy
Investigational use to soften and remodel insulin injection-related lipohypertrophy nodules; very limited evidence.
Androgenic Alopecia
Investigational use for androgenic alopecia; mechanism via local scalp perfusion improvement. Single-arm series only.